Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Single-dose, Randomized, Double-blind, Placebo and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Rapastinel in Healthy, Non-dependent, Adult Recreational Polydrug Users

NCT03799900 is registered in ClinicalTrials.gov with Naurex, Inc, an affiliate of Allergan plc as lead sponsor.

NCT NCT03799900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03799900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Single-dose, Randomized, Double-blind, Placebo and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Rapastinel in Healthy, Non-dependent, Adult Recreational Polydrug Users
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2018
Completion date
March 29, 2019
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human abuse potential